accreditation

Upon completion of the education within the conference, learners will be able to:

• Apply contemporary lipid guidelines to initiate earlier and combination LDL-C-lowering therapy in patients at very high risk
• Integrate Lp(a) testing into routine atherosclerotic CVD (ASCVD) risk assessment and identify which patients are appropriate for emerging targeted therapies
• Implement interprofessional practical clinic workflows that improve lipid goal attainment
• Use risk calculators to guide therapy intensification
• Incorporate CKM staging into CV risk stratification and management
• Implement routine urine creatinine to albumin ratio (UACR) screening to identify cardiorenal risk
• Initiate and comanage sodium-glucose cotransporter 2 (SGLT2) inhibitors, GLP-1 receptor agonists, and mineralocorticoid receptor antagonists (MRAs) for CV risk reduction
• Apply team-based care models to manage patients with overlapping CV, kidney, metabolic, and obesity-related disease
• Apply structured approaches to the longitudinal assessment of patients with atrial fibrillation (AF) and VHD to improve early recognition of disease progression and guide timely intervention
• Differentiate evidence-based management strategies for AF, including appropriate use of rhythm control, anticoagulation, and rate control approaches
• Identify clinical and imaging-based triggers for referral to advanced therapies, including catheter ablation and transcatheter or surgical valve interventions, to optimize timing and patient outcomes
• Integrate interprofessional, patient-centered decision-making strategies to coordinate care across arrhythmia and structural heart pathways and reduce delays in treatment escalation Rapidly initiate and sequence foundational therapies for HFrEF using a real-world, interprofessional approach
• Phenotype patients with HFpEF to guide mechanism-based therapy selection
• Recognize clinical red flags that warrant evaluation or referral for HCM
• Apply guideline-directed antithrombotic strategies across coronary artery disease (CAD), peripheral artery disease (PAD), stroke, and venous thromboembolism (VTE) as part of the interprofessional team
• Identify patients who are most likely to benefit from emerging anticoagulant approaches
• Implement risk-based intensification of therapy in polyvascular disease
• Identify patients with resistant HTN who require evaluation for secondary causes
• Implement evidence-based screening strategies for primary aldosteronism and other secondary etiologies
• Integrate novel pharmacologic and device-based therapies into treatment algorithms as part of the interprofessional team
• Employ interprofessional strategies to integrate current evidence and expert perspectives related to contemporary topics in preventive cardiology to inform individualized CV risk assessment and management